Industries · Healthcare & Life Sciences
Legal talent for biotechnology — where IP, capital markets and the deal cycle meet.
Biotech legal teams track the financing and partnering lifecycle of often pre-revenue companies: venture financings, IPOs and follow-ons, and the collaboration and licensing deals with big pharma that are these companies' lifeblood. The premium hire is counsel who can blend life-sciences IP, securities and complex deal structuring — and that is exactly the search we run.
Hiring here is distinctive because the legal team lives the funding cycle.
Biotech counsel sit at the seam between the science and the capital that funds it. The same lawyer is asked to close a venture financing, structure a collaboration or licensing deal with a pharma partner, protect the patent estate the whole company rests on, and — as the IPO window reopens — get the company public and keep it inside its disclosure obligations.
The frameworks that shape hiring run deep: the USPTO and federal courts for patent prosecution and the BPCIA "patent dance" for biologics; the FDA for IND, breakthrough and orphan designations and the BLA pathway; the SEC for IPOs, follow-ons and public-company reporting around clinical readouts; and contract law governing the collaboration, license, option and milestone agreements that are an emerging biotech's lifeblood. IP is the principal asset, so freedom-to-operate, patent strategy and trade-secret protection sit at the centre of legal value — and the premium roles are rare hybrids of IP plus securities plus deal-making that a generalist search rarely surfaces.
We run this search from both sides. For companies we build in-house legal, IP and compliance functions — see for companies. For firms we place life-sciences IP, securities and transactional partners and practice groups — see for law firms. A lawyer who understands the BPCIA or a biotech IPO is valuable to a biotech GC and to a life-sciences practice alike, and we know both markets.
The capital and dealmaking that turn a legal hire from optional into urgent.
These are the figures hiring committees and candidates are actually reading. They explain why IP, securities and business-development counsel are the premium seats in this sub-sector — and why the brief rewards depth over headcount.
- $26B
- Global biopharma venture investment in 2024 (up from $23.3B in 2023) — the funding base that refills biotech legal and business-development hiring pipelines.
- Alvarez & Marsal, 2024 Global Biopharmaceutical M&A and VC Insights (2024)
- $3.72B
- Capital raised in U.S. biotech IPOs in Q1 2024 alone — roughly six times Q4 2023 — signalling a reopening IPO window that drives securities-counsel demand.
- BioPharma Dive (2024)
- $108B
- Pharma licensing spend in 2024 — the value flowing into biotech-side collaboration and out-licensing transactions that need deal counsel.
- Alvarez & Marsal, 2024 Global Biopharmaceutical M&A and VC Insights (2024)
Biotech legal demand is more capital-markets-sensitive than pharma — it rises and falls with the funding cycle — so the durable hire is counsel whose IP, securities and deal skills transfer across the cycle, not a bet on one financing window. (Alvarez & Marsal / BioPharma Dive, 2024)
The seats that carry the deal and the patent estate.
From the first general counsel to the patent counsel who guards the company's core asset — each role cross-links to the service that runs the search.
General Counsel
Often the first legal hire and the person who has to make a broad remit work alone — financings, partnering, IP oversight, governance and FDA strategy — until the team is large enough to specialise. Reports to the CEO and carries board-level risk.
In-house counsel recruitingHead of IP / Patent Counsel
The seat that protects the company's principal asset. Freedom-to-operate, patent prosecution and the BPCIA 'patent dance' for biologics sit here — every financing and partnership turns on patent strength, so this is rarely a generalist hire.
In-house counsel recruitingSecurities & Capital-Markets Counsel
Owns the IPO and follow-on machinery, public-company reporting and disclosure around clinical readouts. As the IPO window reopens, this is the seat hiring committees move on first — and the one carrying securities-litigation exposure.
In-house counsel recruitingBusiness Development / Transactions Counsel
Structures and negotiates the collaboration, license, option and milestone agreements with big pharma that are an emerging biotech's lifeblood — the high-value work that record pharma licensing spend keeps in front of biotech-side counsel.
In-house counsel recruitingRegulatory & Compliance Counsel
FDA regulatory strategy through IND, breakthrough and orphan designations and the BLA pathway — and the first compliance hire as commercialisation nears. The transition-to-commercial moment is what triggers these seats.
Compliance recruitmentLaw-firm partners & associates
On the firm side we place life-sciences IP, securities and transactional practitioners — patent strategy, BPCIA, capital markets and collaboration experience that maps to the same employers biotech GCs hire from and rely on.
Partner recruitingSix forces that put a name on the hiring plan.
Drawn from the live financing and regulatory landscape of biotechnology — each is a real, recurring reason a legal seat opens, and a reason it has to be filled by someone who has done it before.
- 01
Recovering venture funding refills the pipeline
Biotech legal hiring tracks the funding cycle. Global biopharma venture investment recovered to $26B in 2024, up from $23.3B in 2023 — and that capital is what refills legal and business-development pipelines as financed companies staff up.
- 02
A reopening IPO window drives securities hiring
After a dry spell, the IPO window reopened: U.S. biotech IPOs raised $3.72B in Q1 2024 alone — roughly six times Q4 2023. A live IPO market is the single clearest trigger for securities and capital-markets counsel hiring.
- 03
Record pharma licensing keeps deal counsel busy
Pharma licensing spend reached $108B in 2024, flowing into biotech-side collaboration and out-licensing transactions. These option, license and milestone deals are an emerging biotech's lifeblood — and high-value work for business-development counsel.
- 04
IP is the core asset
Every financing and partnership turns on patent strength, so freedom-to-operate, patent prosecution and trade-secret protection sit at the centre of legal value. That sustains durable patent-counsel demand independent of any single deal.
- 05
Transition-to-commercial triggers new seats
As a product advances toward approval and launch, the company makes its first dedicated FDA-regulatory and compliance hires. The move from clinical-stage to commercial is what opens those seats — and rewards counsel who have made the transition before.
- 06
Cyclicality and rare hybrid profiles
Hiring here is highly cyclical — it contracts sharply in funding winters, and small biotechs often run lean with a single GC plus outside counsel. Roles demand rare hybrids of IP plus securities plus deal-making that are hard to fill from one prior background.
We map the lifecycle before we map the candidates.
Biotech is a clear case for an evidence-led search: the demand is cyclical, the roles demand rare hybrid backgrounds, and the difference between a plausible CV and a real hire is invisible to a generalist.
Before we approach anyone we map the sub-sector: where the company sits in the financing and partnering lifecycle, which regulators and counterparties a candidate has actually faced, the IP, securities and collaboration work they have genuinely run, and the handful of employers that build the relevant depth. That research shapes who we contact and the questions we ask — so the brief is built on the sub-sector's reality, not a generic competency list. It is also how we pressure-test claimed life-sciences IP, BPCIA and capital-markets experience before you ever see a name.
Read our methodology for the research stage in full, or see how we work with in-house counsel and compliance mandates specifically.
Where biotech legal talent moves to and from.
Lawyers in biotech rarely stay in one lane. These adjacent sub-sectors and macro practices share the regulators, the deal flow and the talent pool — and we recruit across all of them.
Pharmaceuticals
FDA, IP and commercial counsel across the drug lifecycle.
View sub-sectorMedical Devices & Diagnostics
Regulatory and product counsel under FDA and global regimes.
View sub-sectorDigital Health
Lawyers where healthcare regulation meets software.
View sub-sectorHospitals & Health Systems
Counsel for providers — fraud and abuse, reimbursement and clinical risk.
View sub-sectorManaged Care & Payers
Regulatory and contracting counsel for insurers and PBMs.
View sub-sectorAdjacent practices
Biotechnology hiring — common questions
Why hire a recruiter who specialises in biotech legal roles?
Because biotech legal hiring tracks a specific lifecycle — venture financings, IPOs and follow-ons, and collaboration and licensing deals with big pharma — and a CV does not tell you whether a lawyer has lived that cycle. The roles demand rare hybrids of life-sciences IP, securities and deal-making that are hard to fill from a single prior background, and IP is the company's principal asset. A specialist reads which regulators a candidate has actually faced — the USPTO, the FDA and the SEC — and whether their patent, capital-markets or partnering experience is real depth. See our methodology for how we apply that lens.
What roles do you place in biotechnology?
General Counsel (often the first legal hire), Head of IP and patent counsel, securities and capital-markets counsel, business-development and transactions counsel for collaborations and licensing, FDA regulatory counsel, and compliance counsel as commercialisation nears. The premium hires are the IP and securities seats — see in-house counsel recruiting and compliance recruitment. On the firm side we place life-sciences IP, securities and transactional partners and associates through partner recruiting.
What is driving biotech legal hiring right now?
Capital and dealmaking. Global biopharma venture investment recovered to $26B in 2024 (Alvarez & Marsal, 2024), up from $23.3B the prior year, refilling legal and business-development pipelines. A reopening IPO window — U.S. biotech IPOs raised $3.72B in Q1 2024 alone, roughly six times Q4 2023 (BioPharma Dive, 2024) — drives securities hiring, while record pharma licensing spend of $108B in 2024 (Alvarez & Marsal, 2024) keeps collaboration and out-licensing counsel busy.
How does the cyclicality of biotech affect who we should hire?
It is the single most important hiring consideration in this sub-sector. Biotech legal demand is more capital-markets-sensitive than pharma — it rises and falls with the funding cycle, contracting sharply in funding winters, and down-rounds, restructurings and shutdowns are common. The lesson for both employers and candidates is to value counsel whose IP, securities and deal skills transfer across the cycle, and to remember that small biotechs often run lean with a single GC plus outside counsel — so the first legal hire has to be unusually broad.
Why is the IP / patent seat treated differently?
Because IP is the company's principal asset. Freedom-to-operate, patent prosecution, trade-secret protection and the BPCIA 'patent dance' for biologics sit at the centre of legal value — every financing and partnership turns on patent strength. That makes patent-counsel demand durable even when deal markets cool, and it raises the calibre of person you need in the seat. We pressure-test claimed life-sciences IP and BPCIA experience before you ever see a name.
I'm a biotech lawyer thinking about a move. Where do I start?
Start confidentially. We work with senior IP, securities, business-development and regulatory counsel — and with law-firm life-sciences practitioners — who want to move within or across the companies and firms they already know. Public-company biotechs also carry meaningful securities-litigation risk around clinical disclosures, which raises the stakes on disclosure counsel and the value of getting your next seat right. You can submit your CV in confidence or read our salary insights to calibrate the market first.
Start a confidential conversation
Build the legal team that funds, protects and partners the science.
Whether you are hiring IP, securities, business-development or regulatory counsel for a biotech — or you are a life-sciences lawyer weighing a move — we listen first, in complete confidence.